Joseph Narus
Research Subjects
Joseph Narus has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
John P. Mulhall
New York City, NY
7 shared publicationsPatricia Guhring
New York, NY
5 shared publications- John P. Mulhall
Memorial Sloan Kettering Cancer Center, New York, NY, USA
4 shared publications Christian J. Nelson
New York, NY
3 shared publicationsMarilyn Parker
New York, NY
3 shared publicationsRaanan Tal
Male Sexual and Reproductive Medicine Program, Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
3 shared publications
Latest Publications
- Open Access
- 1 April 2017
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 197 (4) , e1347
PD69-08 THE IMPACT OF ANDROGEN DEPRIVATION THERAPY ON COMPLIANCE WITH INTRACAVERNOUS INJECTIONS
- 1 April 2017
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 197 (4) , e1347
Open AccessPD69-08 THE IMPACT OF ANDROGEN DEPRIVATION THERAPY ON COMPLIANCE WITH INTRACAVERNOUS INJECTIONS
- 1 April 2015
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 193 (4S)
MP51-05 DEFINING THE INCIDENCE OF POLYCYTHEMIA IN MEN USING INTRAMUSCULAR TESTOSTERONE SUPPLEMENTATION
- 1 April 2015
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 193 (4S)
MP51-05 DEFINING THE INCIDENCE OF POLYCYTHEMIA IN MEN USING INTRAMUSCULAR TESTOSTERONE SUPPLEMENTATION
- 6 June 2014
- Published by Wiley in BJU International
- Vol. 113 (6) , 907-910
Erectile dysfunction in men treated for testicular cancer
Objective: To study the unique characteristics of erectile dysfunction ( ED ) in a population of men who developed ED after testicular cancer ( TC ) diagnosis and treatment. Patients and Methods: All men treated for TC who presented for sexual function evaluation were included in an institutional database. All men underwent standard evaluation including a history/physical examination, completion of the I nternational I ndex of E rectile F unction ( IIEF ) questionnaire, testosterone/gonadotropin measurement and penile duplex D oppler ultrasonography ( DUS ). Results: The study population comprised 76 men whose mean ( sd ) age was 29 (8) years and of whom 25% were married/had a partner. In all, 39% of the patients had seminoma and 61% had non‐seminomatous germ‐cell tumour ( NSGCT ). A total of 66% of patients with seminoma underwent radiation therapy. Of the patients with NSGCT , 79% received chemotherapy, 18% underwent primary retroperitoneal lymph node dissection ( RPLND ) and 20% underwent post‐chemotherapy RPLND . The mean ( sd ) time before seeking sexual medicine consultation was 12 (7) months after treatment completion, the median (range) number of vascular risk factors was 0 (0–2) and the mean ( sd ) remaining testis volume was 16 (8) mL. Mean ( sd ) total testosterone, luteinizing hormone, follicle‐stimulating hormone levels were 312 (186) ng/dL, 9 (7) IU/mL, 17 (12) IU/mL. A total of 26% of patients had total testosterone levels <300 ng/dL. In all, 84% of patients complained primarily of loss of erection‐sustaining capability and 24% had episodes of transient ED before TC diagnosis. The mean ( sd ) IIEF erectile function domain score was 16 (7). All the patients (100%) had a normal DUS . Mean ( sd ) peak systolic and end‐diastolic velocities were 48 (16) and 1.2 (2.2) cm/s, respectively. A total of 88% of patients responded to phosphodiesterase type 5 inhibitor ( PDE 5i) use with erections sufficient for penetration, but 12% did not (mean [ sd ] erectile function domain score 27 [5] vs 17 [6]). There were no differences in haemodynamics between those men with and without hypogonadism. Conclusions: Men with TC presenting with ED after treatment appear uniformly to have normal erectile haemodynamics, suggesting adrenaline‐mediated ED . While the majority of TC survivors with ED respond successfully to PDE 5i, a significant minority do not.
- 6 June 2014
- Published by Wiley in BJU International
- Vol. 113 (6) , 907-910
Erectile dysfunction in men treated for testicular cancer
Objective: To study the unique characteristics of erectile dysfunction ( ED ) in a population of men who developed ED after testicular cancer ( TC ) diagnosis and treatment. Patients and Methods: All men treated for TC who presented for sexual function evaluation were included in an institutional database. All men underwent standard evaluation including a history/physical examination, completion of the I nternational I ndex of E rectile F unction ( IIEF ) questionnaire, testosterone/gonadotropin measurement and penile duplex D oppler ultrasonography ( DUS ). Results: The study population comprised 76 men whose mean ( sd ) age was 29 (8) years and of whom 25% were married/had a partner. In all, 39% of the patients had seminoma and 61% had non‐seminomatous germ‐cell tumour ( NSGCT ). A total of 66% of patients with seminoma underwent radiation therapy. Of the patients with NSGCT , 79% received chemotherapy, 18% underwent primary retroperitoneal lymph node dissection ( RPLND ) and 20% underwent post‐chemotherapy RPLND . The mean ( sd ) time before seeking sexual medicine consultation was 12 (7) months after treatment completion, the median (range) number of vascular risk factors was 0 (0–2) and the mean ( sd ) remaining testis volume was 16 (8) mL. Mean ( sd ) total testosterone, luteinizing hormone, follicle‐stimulating hormone levels were 312 (186) ng/dL, 9 (7) IU/mL, 17 (12) IU/mL. A total of 26% of patients had total testosterone levels <300 ng/dL. In all, 84% of patients complained primarily of loss of erection‐sustaining capability and 24% had episodes of transient ED before TC diagnosis. The mean ( sd ) IIEF erectile function domain score was 16 (7). All the patients (100%) had a normal DUS . Mean ( sd ) peak systolic and end‐diastolic velocities were 48 (16) and 1.2 (2.2) cm/s, respectively. A total of 88% of patients responded to phosphodiesterase type 5 inhibitor ( PDE 5i) use with erections sufficient for penetration, but 12% did not (mean [ sd ] erectile function domain score 27 [5] vs 17 [6]). There were no differences in haemodynamics between those men with and without hypogonadism. Conclusions: Men with TC presenting with ED after treatment appear uniformly to have normal erectile haemodynamics, suggesting adrenaline‐mediated ED . While the majority of TC survivors with ED respond successfully to PDE 5i, a significant minority do not.
- 2 December 2013
- Published by Wiley in BJU International
- Vol. 113 (5b) , E131-E136
Prospective analysis of penile length changes after radical prostatectomy
Objectives: To assess the impact of radical prostatectomy ( RP ) on penile dimensions. To assess the impact of phosphodiesterase‐5 inhibitor ( PDE 5i) use on penile length changes. Patients and Methods: Men undergoing RP were enrolled in this prospective study before surgery. Demographic, clinical and PDE 5i frequency‐of‐use data were collected. Erectile function was measured using the erectile function domain ( EFD ) of the International Index of Erectile Function. A single evaluator measured stretched flaccid penile length ( SFPL ) before RP , and at 2 and 6 months after RP . Repeated measures analysis was used to test differences in SFPL between timepoints. Pearson correlation was used for univariate analyses and multiple regression was used for multivariable analysis. Results: A total of 118 patients were evaluated at baseline, with 76 and 63 patients evaluated at 2 and 6 months, respectively. At 2 months, there was a 2.4‐mm mean decrease in SFPL , while at 6 months there was no significant difference. At 6 months, those subjects who took a daily PDE 5i had no SFPL loss ( n = 36, 1±6.7 mm gain, P = 0.37 compared with baseline), while those subjects who did not consistently take a PDE 5i had SFPL loss ( n = 27, 4.4±6.6 mm loss, P < 0.002 compared with baseline). In multivariable analysis, PDE 5i use at 6 months and 6‐month EFD score without on‐demand PDE 5i were significant predictors of 6‐month SFPL loss, suggesting that an increase in these variables leads to SFPL preservation. Conclusions: In this rigorously conducted prospective study of SFPL changes after RP , there was evidence of SFPL loss at 2 months, but not at 6 months after RP . PDE 5i use moderated SFPL loss, with patients who regularly used PDE 5i having no loss in SFPL .
- 2 December 2013
- Published by Wiley in BJU International
- Vol. 113 (5b) , E131-E136
Prospective analysis of penile length changes after radical prostatectomy
Objectives: To assess the impact of radical prostatectomy ( RP ) on penile dimensions. To assess the impact of phosphodiesterase‐5 inhibitor ( PDE 5i) use on penile length changes. Patients and Methods: Men undergoing RP were enrolled in this prospective study before surgery. Demographic, clinical and PDE 5i frequency‐of‐use data were collected. Erectile function was measured using the erectile function domain ( EFD ) of the International Index of Erectile Function. A single evaluator measured stretched flaccid penile length ( SFPL ) before RP , and at 2 and 6 months after RP . Repeated measures analysis was used to test differences in SFPL between timepoints. Pearson correlation was used for univariate analyses and multiple regression was used for multivariable analysis. Results: A total of 118 patients were evaluated at baseline, with 76 and 63 patients evaluated at 2 and 6 months, respectively. At 2 months, there was a 2.4‐mm mean decrease in SFPL , while at 6 months there was no significant difference. At 6 months, those subjects who took a daily PDE 5i had no SFPL loss ( n = 36, 1±6.7 mm gain, P = 0.37 compared with baseline), while those subjects who did not consistently take a PDE 5i had SFPL loss ( n = 27, 4.4±6.6 mm loss, P < 0.002 compared with baseline). In multivariable analysis, PDE 5i use at 6 months and 6‐month EFD score without on‐demand PDE 5i were significant predictors of 6‐month SFPL loss, suggesting that an increase in these variables leads to SFPL preservation. Conclusions: In this rigorously conducted prospective study of SFPL changes after RP , there was evidence of SFPL loss at 2 months, but not at 6 months after RP . PDE 5i use moderated SFPL loss, with patients who regularly used PDE 5i having no loss in SFPL .
- 1 October 2013
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 10 (10) , 2559-2565
Injection Anxiety and Pain in Men Using Intracavernosal Injection Therapy After Radical Pelvic Surgery
Introduction Intracavernosal injection (ICI) therapy is a well‐recognized treatment strategy with high success rates for men with erectile dysfunction. Despite this, injection anxiety and pain related to injection are significant barriers to its use. Aims This study aims to examine injection anxiety and injection pain in patients using ICI. Methods Men starting ICI therapy post radical pelvic surgery completed questionnaires at initial visit, at each of the two ICI training sessions and at a 4‐month follow‐up visit. Main Outcome Measures Injection Anxiety Scale, Injection Pain Scale, Injection Reaction Inventory, and the Erectile Function Domain of the International Index of Erectile Function. Results Average age of the 68 men was 60 ± 8 years. At 4 months, the self‐reported frequency of ICI use was: 29% P < 0.001). At first injection, 65% reported high injection anxiety (≥5) and this significantly decreased to 42% (P = 0.003) at 4 months. Anxiety at first injection was negatively related to ICI frequency at 4 months (r = −0.23, P = 0.08). Mean injection pain score at first injection was low (2.2 ± 1.8, range 0–10) and 59% rated injection pain ≤2. Injection pain remained consistent across time periods. At first injection, injection anxiety (assessed prior to injection) was related to injection pain (r = 0.21, P = 0.04) and subjects (n = 21) who reported high injection anxiety (≥5) across time points, reported an increase in injection pain scores from first injection to 4 months (2.7 vs. 3.7, P = 0.05). Conclusions Although injection anxiety decreased with ICI use, mean injection anxiety remained at a moderate level (4.4) and 42% of men continued to report “high” injection anxiety at 4 months. While injection pain was low, injection anxiety and pain were related. These data suggest the need for a psychological intervention to help lower injection anxiety related to ICI. Nelson CJ, Hsiao W, Balk E, Narus J, Tal R, Bennett NE, and Mulhall JP. Injection anxiety and pain in men using intracavernosal injection therapy after radical pelvic surgery. J Sex Med 2013;10:2559–2565.
- 1 October 2013
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 10 (10) , 2559-2565
Injection Anxiety and Pain in Men Using Intracavernosal Injection Therapy After Radical Pelvic Surgery
Introduction Intracavernosal injection (ICI) therapy is a well‐recognized treatment strategy with high success rates for men with erectile dysfunction. Despite this, injection anxiety and pain related to injection are significant barriers to its use. Aims This study aims to examine injection anxiety and injection pain in patients using ICI. Methods Men starting ICI therapy post radical pelvic surgery completed questionnaires at initial visit, at each of the two ICI training sessions and at a 4‐month follow‐up visit. Main Outcome Measures Injection Anxiety Scale, Injection Pain Scale, Injection Reaction Inventory, and the Erectile Function Domain of the International Index of Erectile Function. Results Average age of the 68 men was 60 ± 8 years. At 4 months, the self‐reported frequency of ICI use was: 29% P < 0.001). At first injection, 65% reported high injection anxiety (≥5) and this significantly decreased to 42% (P = 0.003) at 4 months. Anxiety at first injection was negatively related to ICI frequency at 4 months (r = −0.23, P = 0.08). Mean injection pain score at first injection was low (2.2 ± 1.8, range 0–10) and 59% rated injection pain ≤2. Injection pain remained consistent across time periods. At first injection, injection anxiety (assessed prior to injection) was related to injection pain (r = 0.21, P = 0.04) and subjects (n = 21) who reported high injection anxiety (≥5) across time points, reported an increase in injection pain scores from first injection to 4 months (2.7 vs. 3.7, P = 0.05). Conclusions Although injection anxiety decreased with ICI use, mean injection anxiety remained at a moderate level (4.4) and 42% of men continued to report “high” injection anxiety at 4 months. While injection pain was low, injection anxiety and pain were related. These data suggest the need for a psychological intervention to help lower injection anxiety related to ICI. Nelson CJ, Hsiao W, Balk E, Narus J, Tal R, Bennett NE, and Mulhall JP. Injection anxiety and pain in men using intracavernosal injection therapy after radical pelvic surgery. J Sex Med 2013;10:2559–2565.
- 30 April 2013
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 189 (4) , e680-e681
1654 COMPLIANCE WITH TRACTION THERAPY IN MEN WITH PEYRONIE'S DISEASE
- 30 April 2013
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 189 (4) , e680-e681
1654 COMPLIANCE WITH TRACTION THERAPY IN MEN WITH PEYRONIE'S DISEASE
- 30 April 2013
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 189 (4S)
1662 PREDICTORS OF ERECTILE DYSFUNCTION (ED) AND HEMODYNAMIC (HD) PARAMETERS AMONG PATIENTS WITH PEYRONIE'S DISEASE (PD)
- 30 April 2013
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 189 (4S)
1662 PREDICTORS OF ERECTILE DYSFUNCTION (ED) AND HEMODYNAMIC (HD) PARAMETERS AMONG PATIENTS WITH PEYRONIE'S DISEASE (PD)